2 results
Approved WMOCompleted
Lu AF28996 is an orally administered investigational compound of a potent, long-acting dopamine agonist, Lu AA40326, currently under development by H. Lundbeck A/S for the treatment of Parkinson*s disease (PD). Primary Objective:to investigate the…
Approved WMOPending
Primary Objective:The primary objective is to investigate whether the retinal SpO2 - measured with invisible, NIR light - changes as a function of simulated height in the same way as the SpO2 measured with the standard finger clip.Secondary…